By Kamal Choudhury (Reuters) – Edwards Lifesciences raised its 2025 sales forecast on Wednesday after a quarterly beat, driven by robust demand for its artificial heart valves and other medical equipment. The company has revised its 2025 sales forecast upwards to a range of $5.7 billion to $6.1 billion, from the previously projected $5.6 billion […]
Health
Edwards Lifesciences raises 2025 sales forecast after robust quarter
Audio By Carbonatix
By Kamal Choudhury
(Reuters) – Edwards Lifesciences raised its 2025 sales forecast on Wednesday after a quarterly beat, driven by robust demand for its artificial heart valves and other medical equipment.
The company has revised its 2025 sales forecast upwards to a range of $5.7 billion to $6.1 billion, from the previously projected $5.6 billion to $6.0 billion, reflecting recent changes in foreign exchange rates.
Investors and analysts are closely monitoring how medical device makers will handle tariffs and whether they expect benefits from foreign currency fluctuations.
Edwards expects a tariff impact of 5 cents per share for 2025, with a larger hit expected in 2026.
“We may not be as complex as some others, because we operate just a handful of production facilities that are strategically located with our key business regions,” said Chief Financial Officer Scott Ullem.
The company operates manufacturing facilities in the United States, Singapore, Costa Rica and Ireland, as per its regulatory filing.
However, any changes or new tariffs, assuming the existing ones remain in place for the rest of 2025, could have a “material” impact on the firm’s future financial outcomes and forecast, the company said.
Edwards reaffirmed its 2025 adjusted per-share profit of $2.40 to $2.50, taking into account the $1.2 billion deal to buy heart device makers JenaValve and Endotronix, and tariff impact.
The company said it expects pressure on its operating margin as a result of the weakening dollar, the impact of announced tariffs and the expected close of the JenaValve acquisition.
Earlier on Wednesday, larger peer Boston Scientific raised its annual profit forecast, stating strong product demand would counterbalance a potential $200 million hit from tariffs.
On an adjusted basis, the medical device maker reported a profit of 64 cents per share, beating analysts’ estimates of 60 cents per share.
For the first quarter, the company reported revenue of $1.41 billion, compared to estimates of $1.40 billion.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Mohammed Safi Shamsi)